Background: Acute HIV infection is highly transmissible yet often missed by antibody‐only rapid tests. Rwanda adopted fourth‐generation antigen/antibody (Ag/Ab) tests in 2016, but routine p24 antigen documentation remains limited, limiting acute/early infection estimates. This study characterized acute/early HIV infection among key populations, including female sex workers (FSW), men who have sex with men (MSM), and people who inject drugs (PWID), to inform targeted testing and prevention interventions. Methods: We conducted a cross‐sectional study in 2025 across 25 health facilities in 12 Rwandan districts. Individuals aged ≥ 15 years with unknown HIV status from FSW, MSM, PWID, and adolescent girls and young women (AGYW) were recruited via snowball sampling. Structured RedCap questionnaires captured socio‐demographic, behavioral, and HIV testing history data. HIV testing followed the national serial algorithm using fourth‐generation Determine HIV Early Detect rapid tests; acute/early infection required p24 antigen positivity regardless of antibody status. Results: Among 1341 participants (median age 25 years, interquartile range [IQR]: 21–30), 864 (64%) were FSW, 177 (13%) were MSM, 58 (4.3%) were PWID, and 242 (18%) were AGYW; 66% had only primary education and 55% resided in rural areas. In the prior 4 weeks, 52% reported multiple sexual partners and 35.5% reported consistent condom use. One‐third (416, 32.8%) were aware of pre‐exposure prophylaxis (PrEP), and 34.7% (141/406) had ever used it. Overall HIV positivity was 5.0% (67/1341); acute/early HIV infection yield was 0.45% (6/1341), with two‐thirds of cases (4/6) among MSM, all from Kigali City. Half (3/6) of acute/early cases reported inconsistent condom use and none reported PrEP use. Conclusion: Acute and early HIV infections appear more common among MSM in Kigali, potentially associated with ongoing risk behaviors and low PrEP uptake, although this observation is based on a small number of cases. Priorities include strengthened acute HIV surveillance via fourth‐generation and self‐testing, rapid antiretroviral therapy (ART) initiation, and scaled‐up tailored prevention, especially PrEP.